{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:53:47Z","timestamp":1788173627597,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.semarthrit.2017.10.009","type":"journal-article","created":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T07:46:13Z","timestamp":1507967173000},"page":"630-638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study"],"prefix":"10.1016","volume":"47","author":[{"given":"Evo","family":"Alemao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenchao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Frits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine K.","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy A.","family":"Shadick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Weinblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2017.10.009_bib1","unstructured":"Rheumatoid Arthritis (RA). Available at: https:\/\/www.rheumatoidarthritis.org\/ra\/. Last accessed April 27, 2017."},{"key":"10.1016\/j.semarthrit.2017.10.009_bib2","first-page":"161","article-title":"Rheumatoid arthritis: early diagnosis and treatment outcomes","volume":"2","author":"Heidari","year":"2011","journal-title":"Caspian J Intern Med"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib3","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar4540","article-title":"Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study","volume":"16","author":"Innala","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3109\/s10165-012-0718-6","article-title":"Ethnic differences in the prognostic utility of rheumatoid factor isotypes and anticyclic citrullinated peptides in rheumatoid arthritis patients: a cross-sectional study","volume":"23","author":"Gomez","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib5","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3899\/jrheum.100267","article-title":"Relative clinical influence of clinical, laboratory, and radiological investigations in early arthritis on the diagnosis of rheumatoid arthritis. Data from the French Early Arthritis Cohort ESPOIR","volume":"37","author":"Gossec","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib6","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.22353","article-title":"Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis","volume":"55","author":"Finckh","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/ard.2009.121160","article-title":"A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study","volume":"69","author":"Visser","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib10","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","article-title":"A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis","volume":"48","author":"Vastesaeger","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib11","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.24827","article-title":"Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis","volume":"61","author":"Aggarwal","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib12","doi-asserted-by":"crossref","first-page":"R40","DOI":"10.1186\/ar4469","article-title":"Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year","volume":"16","author":"Kay","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib13","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.2174\/1568026614666141215152733","article-title":"The use of citrullinated peptides for the diagnosis and prognosis of rheumatoid arthritis","volume":"14","author":"Haro","year":"2014","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib14","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3899\/jrheum.111152","article-title":"Anticitrullinated protein antibody, but not its titer, is a predictor of radiographic progression and disease activity in rheumatoid arthritis","volume":"39","author":"Shiozawa","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib15","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1136\/ard.2003.017574","article-title":"Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations","volume":"63","author":"De Rycke","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib16","first-page":"423","article-title":"Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis","volume":"34","author":"Yildirim","year":"2004","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib17","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/ard.2003.014233","article-title":"Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP)","volume":"63","author":"Forslind","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/ard.62.2.120","article-title":"Anticitrullinated protein\/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage","volume":"62","author":"Meyer","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib19","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1002\/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6","article-title":"The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis","volume":"43","author":"Kroot","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3899\/jrheum.121521","article-title":"Flares in rheumatoid arthritis: frequency and management. A report from the BRASS registry","volume":"41","author":"Bykerk","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/rheumatology\/keq263","article-title":"Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women\u2019s Hospital Rheumatoid Arthritis Sequential Study","volume":"50","author":"Iannaccone","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib22","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/acr.21940","article-title":"Factors associated with attrition in a longitudinal rheumatoid arthritis registry","volume":"65","author":"Iannaccone","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib23","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/ar4439","article-title":"ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial","volume":"16","author":"Seegobin","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib24","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/annrheumdis-2011-200736","article-title":"Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study)","volume":"16","author":"Wyers-de Boer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib25","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/art.23439","article-title":"Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies","volume":"58","author":"de Vries-Bouwstra","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/annrheumdis-2011-200379","article-title":"The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study","volume":"71","author":"van den Broek","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib27","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/rheumatology\/kes184","article-title":"Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis","volume":"51","author":"Canhao","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/ard.2007.084715","article-title":"BRAGGSS: Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis","volume":"68","author":"Potter","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib29","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1136\/annrheumdis-2011-201109","article-title":"Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the \u2018Orencia and Rheumatoid Arthritis\u2019 registry","volume":"71","author":"Gottenberg","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","article-title":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis","volume":"72","author":"Isaacs","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib31","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00296-015-3271-8","article-title":"Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis","volume":"35","author":"Katchamart","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib32","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/art.27533","article-title":"Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis","volume":"62","author":"Ercan","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2174\/1573397110666150120102928","article-title":"Association of anti-cyclic citrullinated peptide antibodies with clinical and radiological disease severity in rheumatoid arthritis","volume":"10","author":"Gupta","year":"2015","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib34","doi-asserted-by":"crossref","first-page":"728610","DOI":"10.1155\/2015\/728610","article-title":"The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysis","volume":"2015","author":"Jilani","year":"2015","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12891-015-0587-1","article-title":"Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis","volume":"16","author":"Ally","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/1756-185X.12129","article-title":"Anti-citrullinated protein antibodies and their clinical utility in rheumatoid arthritis","volume":"16","author":"Farid","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/ard.2007.071662","article-title":"Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study","volume":"67","author":"Karlson","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/17402520500233510","article-title":"The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis","volume":"12","author":"Shovman","year":"2005","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib39","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrrheum.2009.157","article-title":"Prognostic factors in rheumatoid arthritis in the era of biologic agents","volume":"5","author":"Skapenko","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s13075-015-0736-9","article-title":"Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials","volume":"17","author":"Aletaha","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180655","article-title":"Anti-citrullinated protein antibody positive rheumatoid arthritis is primarily determined by rheumatoid factor titre and the shared epitope rather than smoking per se","volume":"12","author":"Murphy","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/ard.2005.038851","article-title":"The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis","volume":"65","author":"Chen","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib43","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/ar1851","article-title":"Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study","volume":"8","author":"Atzeni","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib44","first-page":"1067","article-title":"Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis","volume":"26","author":"Cuchacovich","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib45","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3899\/jrheum.101241","article-title":"Cartilage oligomeric matrix protein associates differentially with erosions and synovitis and has a different temporal course in cyclic citrullinated peptide antibody (anti-CCP)-positive versus anti-CCP-negative early rheumatoid arthritis","volume":"38","author":"Christensen","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.10.009_bib46","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10067-011-1711-8","article-title":"Association of anticyclic citrullinated peptide antibodies with extra-articular manifestations, gender, and tabagism in rheumatoid arthritis patients from southern Brazil","volume":"30","author":"Goeldner","year":"2011","journal-title":"Clin Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217303591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217303591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T23:01:26Z","timestamp":1535324486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017217303591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0049017217303591"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.10.009","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}